We are live on ! Find out more
ENGN icon

enGene Therapeutics
ENGN

37 hedge funds and large institutions have $279M invested in enGene Therapeutics in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more capital invested

Capital invested by funds: $147M → $279M (+$132M)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

3% more funds holding

Funds holding: 36 → 37 (+1)

0.74% more ownership

Funds ownership: 79.07% → 79.81% (+0.74%)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

Holders
37
Holders Change
+1
Holders Change %
+2.78%
% of All Funds
0.49%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
7
Increased
7
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
+$10.3M
2
PA
Perceptive Advisors
New York
+$9.56M
3
FLSM
Frazier Life Sciences Management
California
+$5.28M
4
MB
MPM BioImpact
Massachusetts
+$2.42M
5
Morgan Stanley
Morgan Stanley
New York
+$376K

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$10.6M
2
Bank of America
Bank of America
North Carolina
-$6.19M
3
Goldman Sachs
Goldman Sachs
New York
-$3.43M
4
O
OrbiMed
New York
-$2.47M
5
BOCH
Blue Owl Capital Holdings
New York
-$2.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
SSA
26
Schonfeld Strategic Advisors
New York
$171K -$682K -149,500 -86%
Millennium Management
27
Millennium Management
New York
$140K +$34.1K +7,472 +57%
Wells Fargo
28
Wells Fargo
California
$122K +$67.1K +14,711 +460%
PFCS
29
Pale Fire Capital SE
Czech Republic
$118K – – –
Hudson Bay Capital Management
30
Hudson Bay Capital Management
Connecticut
$75.6K +$50.5K +11,074 New
Toronto Dominion Bank
31
Toronto Dominion Bank
Ontario, Canada
$68.3K -$20.7K -4,537 -31%
Raymond James Financial
32
Raymond James Financial
Florida
$68.3K +$36.2K +7,932 +384%
PP
33
PFS Partners
New Jersey
$61.5K +$41K +9,000 New
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$54K – – –
MCM
35
MAI Capital Management
Ohio
$5.3K -$9.8K -2,149 -73%
SS
36
SBI Securities
Japan
$212 +$5 +1 +3%
Citigroup
37
Citigroup
New York
$7 +$5 +1 New
O
38
OrbiMed
New York
– -$2.47M -677,977 Closed
ACM
39
ADAR1 Capital Management
Texas
– -$101K -27,787 Closed
Renaissance Technologies
40
Renaissance Technologies
New York
– -$41.5K -11,400 Closed
PP
41
Paloma Partners
Connecticut
– -$37.6K -10,319 Closed
WAM
42
Wolverine Asset Management
Illinois
– -$23.2K -6,361 Closed
NS
43
NBC Securities
Alabama
– -$1K -380 Closed
1
2

ENGN Hedge Fund Activity: Q3 2025 in Review

37 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q3 2025, worth a combined $279M — up 90% from $147M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ENGN positions and 6 closed out — a net gain of 1 holder — while 7 added to existing stakes and 8 trimmed.

The largest buyer was Braidwell, opening a new position worth an estimated $10.3M. The largest seller was Deep Track Capital, cutting an estimated $10.6M.

  • 37 institutional investors held enGene Therapeutics (ENGN) as of Q3 2025, up from 36 in Q2 2025.
  • Funds reported $279M of enGene Therapeutics stock for Q3 2025, up 90% quarter-over-quarter.
  • 7 funds opened new enGene Therapeutics positions in Q3 2025 and 6 closed out, a net change of +1 holder.
  • The largest enGene Therapeutics buyer in Q3 2025 was Braidwell, an estimated $10.3M added.
  • The largest enGene Therapeutics seller in Q3 2025 was Deep Track Capital, an estimated $10.6M sold.

Based on aggregated 13F filings for Q3 2025.